20/20 Biolabs, Inc. (AIDX) stock
AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3068% below fair value
$0.19−0.00 (-1.01%)
Close on Nov 18, 2026Market cap $2.37MP/E –Yield –
20/20 Biolabs net income
Net income is the profit left for shareholders after every expense, interest and tax.
For fiscal 2025 it was -$3.74M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$3.74M | – |
| FY2024 | Dec 31, 2024 | -$5.55M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.51M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.17M | – |
| Q2 FY2025 | Jun 30, 2025 | -$840.93K | – |
| Q1 FY2025 | Mar 31, 2025 | -$764.58K | – |
See a number that looks wrong?